The myasthenia gravis treatment landscape is expanding with new therapies and mechanisms, enhancing management options. Treatment decisions are complex due to patient heterogeneity and idiosyncratic ...
Lisocabtagene maraleucel (liso-cel), a CAR T cell therapy, achieved an overall response rate of 97% in the TRANSCEND FL study Durable benefits persisted at three years and showed a favorable long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results